GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Cyclically Adjusted Price-to-FCF

ELTP (Elite Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Jul. 04, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Elite Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Elite Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Elite Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Elite Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

Elite Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Elite Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Elite Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.003/134.9266*134.9266
=0.003

Current CPI (Mar. 2025) = 134.9266.

Elite Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.001 100.684 0.001
201509 -0.005 100.392 -0.007
201512 -0.003 99.792 -0.004
201603 0.000 100.470 0.000
201606 -0.001 101.688 -0.001
201609 -0.003 101.861 -0.004
201612 -0.001 101.863 -0.001
201703 -0.005 102.862 -0.007
201706 -0.002 103.349 -0.003
201709 -0.003 104.136 -0.004
201712 0.000 104.011 0.000
201803 -0.001 105.290 -0.001
201806 -0.002 106.317 -0.003
201809 -0.002 106.507 -0.003
201812 -0.002 105.998 -0.003
201903 -0.003 107.251 -0.004
201906 0.000 108.070 0.000
201909 -0.001 108.329 -0.001
201912 0.000 108.420 0.000
202003 -0.001 108.902 -0.001
202006 0.001 108.767 0.001
202009 0.002 109.815 0.002
202012 0.001 109.897 0.001
202103 -0.001 111.754 -0.001
202106 0.002 114.631 0.002
202109 0.000 115.734 0.000
202112 0.003 117.630 0.003
202203 0.001 121.301 0.001
202206 -0.001 125.017 -0.001
202209 -0.004 125.227 -0.004
202212 -0.001 125.222 -0.001
202303 0.002 127.348 0.002
202306 -0.003 128.729 -0.003
202309 0.000 129.860 0.000
202312 -0.002 129.419 -0.002
202403 0.002 131.776 0.002
202406 0.001 132.554 0.001
202409 0.001 133.029 0.001
202412 -0.001 133.157 -0.001
202503 0.003 134.927 0.003

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Elite Pharmaceuticals  (OTCPK:ELTP) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Elite Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Executives
Douglas Plassche officer: Executive VP of Operations 165 LUDLOW AVE., NORTHVALE NJ 07647
Mark N Pellegrino officer: CFO, Secretary, Treasurer 165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov officer: Chief Commercial Officer 165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J officer: CFO, Secretary, Treasurer 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman officer: CFO, Secretary, Treasurer C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer director C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel director 93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc 10 percent owner 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine director, 10 percent owner C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye director, 10 percent owner, officer: Chief Scientific Officer C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc 10 percent owner 227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc 10 percent owner 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim director, 10 percent owner, officer: President & CEO C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647